This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser.
Print Document
Reports
Cover Page
Audit Information
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements of Operations and Comprehensive (Loss) Income
Consolidated Statements of Stockholders' Equity
Consolidated Statements of Cash Flows
Reports
Organization and Significant Accounting Policies
Revenue Recognition
Balance Sheet Accounts
Investments
Intangible Assets
Stockholders' Equity
Commitments and Contingencies
Equity Method Investment
Leases
Stock-Based Compensation
Fair Value Measurements
Income Taxes
Employee Benefit Plans
Liability Related to the Sale of Future Royalties
Financing Agreement
Convertible Notes
Net Loss Per Share
Segment Information
Subsequent Events
Insider Trading Arrangements
Insider Trading Policies and Procedures
Cybersecurity Risk Management and Strategy Disclosure
Accounting Policies
Organization and Significant Accounting Policies (Policies)
Tables
Organization and Significant Accounting Policies (Tables)
Revenue Recognition (Tables)
Balance Sheet Accounts (Tables)
Investments (Tables)
Intangible Assets (Tables)
Stockholders' Equity (Tables)
Leases (Tables)
Stock-Based Compensation (Tables)
Fair Value Measurements (Tables)
Income Taxes (Tables)
Liability Related to the Sale of Future Royalties (Tables)
Financing Agreement (Tables)
Convertible Notes (Tables)
Net Loss Per Share (Tables)
Segment Information (Tables)
Details
Organization and Significant Accounting Policies - Narrative (Details)
Organization and Significant Accounting Policies - Useful Lives of Property, Plant and Equipment (Details)
Revenue Recognition - Revenue (Details)
Revenue Recognition - Product Revenue (Details)
Revenue Recognition - Receivables and Contract Liabilities (Details)
Revenue Recognition - Deferred Revenue (Details)
Revenue Recognition - Sarepta Therapeutics, Inc. (Details)
Revenue Recognition - Novartis Pharma AG (Details)
Revenue Recognition - Visirna Therapeutics Inc. (“Visirna”) and Genzyme Corporation (“Sanofi”) (Details)
Revenue Recognition - Madrigal Pharmaceuticals, Inc. (“Madrigal”) (Details)
Revenue Recognition - GlaxoSmithKline Intellectual Property (No. 3) Limited (Details)
Revenue Recognition - Takeda Pharmaceutical Company Limited (Details)
Revenue Recognition - Amgen, Inc. (Details)
Balance Sheet Accounts - Property, Plant and Equipment (Details)
Balance Sheet Accounts - Narrative (Details)
Balance Sheet Accounts - Inventory (Details)
Balance Sheet Accounts - Accrued Expenses (Details)
Investments - Available-for-Sale Securities (Details)
Investments - Contract Maturity of Available-for-Sale Securities (Details)
Investments (Details) - Narrative (Details)
Intangible Assets - Intangible Assets (Details)
Intangible Assets - Narrative (Details)
Intangible Assets - Expected Future Amortization (Details)
Stockholders' Equity - Shares of Common Stock and Preferred Stock (Details)
Stockholders' Equity - Narrative (Details)
Commitments and Contingencies (Details)
Equity Method Investment (Details)
Leases - Narrative (Details)
Leases - Components of Lease Assets and Liabilities (Details)
Leases - Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)
Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)
Stock-Based Compensation - Narrative (Details)
Stock-Based Compensation - Granted and Outstanding Awards (Details)
Stock-Based Compensation - Expenses Included in Operating Expenses (Details)
Stock-Based Compensation - Summarized Information about Stock Options (Details)
Stock-Based Compensation - RSUs Activity (Details)
Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
Fair Value Measurements - Narrative (Details)
Income Taxes - Components of Income (Loss) Before Income Taxes (Details)
Income Taxes - Income Tax Provision (Benefit) (Details)
Income Taxes - Effective Income Tax Rate Reconciliation (Details)
Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)
Income Taxes - Narrative (Details)
Income Taxes - Income Taxes Paid, Net of Refunds Received (Details)
Income Taxes - Gross Unrecognized Tax Benefits (Details)
Employee Benefit Plans (Details)
Liability Related to the Sale of Future Royalties - Narrative (Details)
Liability Related to the Sale of Future Royalties - Liability Related to Sale of Future Royalties (Details)
Financing Agreement - Narrative (Details)
Financing Agreement - Outstanding Balance of Credit Facility (Details)
Financing Agreement - Interest Expense Recognized Related to Credit Facility (Details)
Financing Agreement - Principal Repayment Related to Credit Facility (Details)
Convertible Notes - Narrative (Details)
Convertible Notes - Schedule of Convertible Debt (Details)
Convertible Notes - Schedule of Interest Expense Recognized Related to Notes (Details)
Net Loss Per Share - Basic and Diluted Net Income (Loss) Per Share (Details)
Net Loss Per Share - Antidilutive Securities (Details)
Segment Information - Narrative (Details)
Segment Information - Financial Information of Reportable Segment (Details)
Subsequent Events (Details)
All Reports